Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-dose therapy in multiple myeloma

D Samson1

  • 1Department of Haematology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.

Current Opinion in Hematology
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Social sleepers: The effects of social status on sleep in terrestrial mammals.

Hormones and behavior·2022
Same author

Recurrence of infection and hernia following partial versus complete removal of infected hernia mesh: a systematic review and cohort meta-analysis.

Hernia : the journal of hernias and abdominal wall surgery·2019
Same author

Retrograde crossing stent placement strategies at the basilar apex for the treatment of wide necked aneurysms: reconstructive and deconstructive opportunities.

Journal of neurointerventional surgery·2011
Same author

Novel sequence tagged sites from the human 8p12-p21 chromosomal region involved in breast cancer.

Oncology reports·2011
Same author

Rapid Identification of Mycobacterium tuberculosis and nontuberculous mycobacteria by multiplex, real-time PCR.

Journal of clinical microbiology·2009
Same author

Preoperative embolization of cerebral arteriovenous malformations with onyx.

AJNR. American journal of neuroradiology·2008
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Autologous stem cell transplant improves survival for multiple myeloma but doesn't cure it, with most patients relapsing. Purging contaminating myeloma cells from stem cell harvests is a key research focus to improve outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Transplantation

Background:

  • Autologous transplantation prolongs survival in multiple myeloma compared to chemotherapy but is not curative.
  • Relapse within 5 years is common, with contaminating myeloma cells in stem cell harvests potentially causing recurrence.
  • Allogeneic transplantation has lower relapse rates but higher mortality; a graft-versus-myeloma effect is observed.

Purpose of the Study:

  • To explore strategies for improving outcomes in multiple myeloma treatment.
  • To investigate the role of stem cell purging in preventing relapse after autologous transplantation.
  • To evaluate the efficacy of allogeneic transplantation and graft-versus-myeloma effects.

Main Methods:

  • Review of outcomes for autologous stem cell transplantation in multiple myeloma.

Related Experiment Videos

  • Analysis of stem cell harvests for contaminating myeloma cells.
  • Comparison of relapse rates and mortality between autologous and allogeneic transplantation.
  • Assessment of donor lymphocyte infusions in relapsed patients.

    • Main Results:

    • Autologous transplantation offers survival benefits but not a cure for multiple myeloma.
    • Myeloma cells frequently contaminate stem cell harvests, posing a relapse risk.
    • Allogeneic transplantation demonstrates a lower relapse risk but higher treatment-related mortality.
    • Donor lymphocyte infusion shows efficacy in patients relapsing post-allogeneic transplant.

    Conclusions:

    • Stem cell purging is a critical area of investigation to enhance autologous transplant efficacy.
    • The graft-versus-myeloma effect offers a potential therapeutic avenue for multiple myeloma.
    • Further research is needed to optimize stem cell transplantation strategies for multiple myeloma cure.